Wim H.J. Kruit - Concepedia

Author

Wim H.J. Kruit

Also Known As

W H J Kruit, W H Kruit, W Kruit, W. H. J. KRUIT, W. H. J. Kruit, W. Kruit, W.H. Kruit, W.H.J Kruit, W.H.J. Kruit, Wim H J Kruit

112

Publications

6.8K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Cancer Institute Radboud University Nijmegen Rotterdam University of Applied Sciences Radboud University Medical Center Erasmus University Rotterdam

About

Wim H.J. Kruit is an author at Erasmus MC Cancer Institute specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	33	2.9K
2	Health Sciences	3	3	224
3	Allergy	1	1	26
4	Cell Biology	1	1	26
5	Cellular Therapies	1	1	13

Wim H.J. Kruit

Publications

Citations

H-Index

Page 1

	Year	Citations
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami, The Lancet Surgical OncologyMedicineEortc 18991MelanomaImmunology	2008	638
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier, Journal of Clinical Oncology Pretreatment ExpressionImmunologyImmunoeditingPathologyPredictive Gene Signature	2013	461
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Alexander M.M. Eggermont, Stefan Suciu, Rona M. MacKie, The Lancet Surgical OncologyOncologyMelanomaImmunologyClinical Trials	2005	310
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Journal of Clinical Oncology	2012	279
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma Wim H.J. Kruit, Stefan Suciu, Brigitte Dréno, Journal of Clinical Oncology	2013	217
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032) Poulam M. Patel, Stefan Suciu, Laurent Mortier, European Journal of Cancer Eortc 18032MedicineMelanomaPharmacotherapyCancer Treatment	2011	209
Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial Henrik Schmidt, Stefan Suciu, Cornelis J.A. Punt, Journal of Clinical Oncology	2007	190
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial Brigitte Dréno, John F Thompson, B. Mark Smithers, The Lancet Oncology Tumor ImmunologyCancer ImmunosurveillanceMedicineMelanomaImmunology	2018	190
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients Ivar Bleumer, Alexander Knuth, Egbert Oosterwijk, British Journal of Cancer	2004	173
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report M. Marchand, Cornelis J.A. Punt, Steinar Aamdal, European Journal of Cancer Cancer ImmunosurveillanceMedicineImmunologyClinical ReportMage-3 Protein	2002	167

Page 1